English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

After a preliminary explanation as to how I came to know Andy Grieve and some remarks about his career and mine and how they have intersected, I consider the design and analysis of trials of vaccines for COVID‐19 for the purpose of estimating efficacy. Five large trials, run by the sponsors Pfizer/BioNTech, AstraZeneca/Oxford University, Moderna, Novavax and J&J Janssen are considered briefly. Frequentist approaches to analysis were used for four of the trials but Pfizer/BioNTech nominated a Bayesian approach. The design and analysis of this trial is considered in some detail, in particular as regards the choice of prior distribution. I conclude by drawing some general lessons.

The design and analysis of vaccine trials for COVID ‐19 for the purpose of estimating efficacy